MedTrace Logo

Lessening Organ Dysfunction With VITamin C - COVID-19

NCT04401150 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2023-04-21

No results posted yet for this study

Summary

LOVIT-COVID is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at 28 days in hospitalized COVID-19 patients.

Conditions

  • Vitamin C
  • COVID-19
  • Hospitalized Patients

Interventions

DRUG

Vitamin C

Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).

DRUG

Control

Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.

Sponsors & Collaborators

  • Lotte & John Hecht Memorial Foundation

    collaborator OTHER

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • François Lamontagne, MD, FRCPC, MSc · Université de Sherbrooke and CIUSSS de l'Estrie - CHUS

  • Neill K Adhikari, MDCM, FRCPC, MSc · Sunnybrook Health Sciences Centre, University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-14
Primary Completion
2022-07-15
Completion
2022-12-06

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04401150 on ClinicalTrials.gov